Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Propylallyltryptamine

Add links
From Wikipedia, the free encyclopedia
(Redirected from PALT)
Propylallyltryptamine
Clinical data
Other namesPALT; N-Propyl-N-allyltryptamine; ASR-3004; ASR3004
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist
ATC code
  • None
Identifiers
  • N-[2-(1H-indol-3-yl)ethyl]-N-prop-2-enylpropan-1-amine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC16H22N2
Molar mass242.366 g·mol−1
3D model (JSmol)
  • CCCN(CCC1=CNC2=CC=CC=C21)CC=C
  • InChI=1S/C16H22N2/c1-3-10-18(11-4-2)12-9-14-13-17-16-8-6-5-7-15(14)16/h3,5-8,13,17H,1,4,9-12H2,2H3
  • Key:BPHDZENPKNMIRD-UHFFFAOYSA-N

Propylallyltryptamine (PALT), also known as N-propyl-N-allyltryptamine or by its developmental code name ASR-3004, is a serotonin receptor modulator of the tryptamine family.[1] It is an asymmetrical analogue of dipropyltryptamine (DPT) and diallyltryptamine (DALT).[1] The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT6 receptors, but not of the serotonin 5-HT1A receptor.[1] It is also a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI).[1] The chemical synthesis of PALT has been described.[1] A notable analogue of PALT is iPALT (ASR-3003).[1] PALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024.[1]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 6 7 US 20240277665A1, Daley PF, Cozzi NV, Callaway WB, "Asymmetric allyl tryptamines", issued 4 March 2024, assigned to Alexander Shulgin Research Institute Inc.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Propylallyltryptamine&oldid=1360364400"